Skip to main content

MetaHistoryBook Browse Today Discover Create

Language

Loading…

Sun & Rain Works

Est. 2005 · Eugene, OR

nivolumab — MetaHistoryBook

nivolumab

Cancer drug, Anti PD-1 monoclonal antibody

Wikipedia ↗Wikidata (Q7041828) ↗

Details

Instance of: type of chemical entity
Subclass of: chemical compound
active ingredient in: Nivolumab Bms, Opdivo
has characteristic: biopharmaceutical
has use: medication
LiverTox likelihood score: LiverTox toxicity likelihood category E*
medical condition treated: head and neck squamous cell carcinoma, myelodysplastic syndrome, acute myeloid leukemia, non-small-cell lung carcinoma, benign mesothelioma, lymphoma, metastatic melanoma, diffuse large B-cell lymphoma, tongue squamous cell carcinoma, renal clear cell carcinoma, secondary neoplasm, squamous cell carcinoma of the lung
physically interacts with: programmed cell death 1
subject has role: antineoplastic, monoclonal antibody
World Health Organisation international non-proprietary name: nivolumab

Connected on Wikidata

Subject of

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nivolumab Plus Radiotherapy in Advanced Melanoma

Nothing in the MetaHistoryBook collection references this item yet.

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC